6 Jan 2020 07:15
6 January 2020
NMC Health plc
(the "Company" or "NMC")
Announcement of Independent Review Oversight Committee
NMC Health plc (LSE: NMC) confirms that the Committee that will oversee the independent third-party Review announced by the Company on 23 December 2019, will be made up of the following Independent Non-Executive Directors:
Jonathan Bomford (Chair)
Tarek Alnabulsi
Lord Clanwilliam
Salma Hareb
The appointment of independent advisers to undertake the Review is currently being progressed and is expected to be confirmed shortly. The Review will focus initially on confirmation of the Group's cash balances as at 15 December 2019 and this will be published as soon as possible. The remainder of the Review is expected to be completed, and its findings published, well in advance of the finalisation and announcement of the Company's 2019 full year results.
In the meantime, we remain focused on our business, strategy and wider stakeholders and in continuing to generate long-term returns and value for our shareholders.
Contacts
NMC |
|
Asjad Yahya, Investor Relations | +971 (0)56 219 0975 |
Media | |
FTI Consulting, London | |
Edward Bridges / Simon Conway / Victoria Foster Mitchell | +44 (0)20 3727 1000 |
FTI Consulting, Gulf | |
Shane Dolan | +971 (0)4 437 2100 |
About NMC Health
NMC is one of the leading private healthcare operators in the Gulf Cooperation Council ("GCC") with an international network of multi-specialty inpatient and outpatient clinics and hospitals, specialized maternity and fertility clinics, and long-term care homes hospitals across nineteen countries. NMC also ranks as one of the top two in-vitro fertilisation operators globally. The NMC Health group is recognised as a leading provider of long-term medical care in the UAE through its subsidiary ProVita. Pursing a selective international expansion programme since 2016, NMC has total capacity of 2,207 licensed beds across its network. Moreover, the recent formation of a joint venture with GOSI/Hassana Investment Company provides a solid platform for continued growth in the GCC region's largest healthcare market. The NMC Health group treated over 7.5 million patients in 2018. The NMC Health group is also a leading UAE supplier of products and consumables coming from healthcare related products. NMC reported revenues of US$2.1 billion for the year ended 31 December 2018.
In April 2012, NMC was listed on the Premium Segment of the London Stock Exchange. NMC is a constituent of the FTSE 100 Index.